Ucb S.A. · EURONEXT:UCB

Ucb — Investor Presentation (April 2011)

63 slides from Ucb's investor presentation, April 2011

  1. Slide 1: Progressing to become the patient-centric global biopharma leader

    Slide 1: Progressing to become the patient-centric global biopharma leader

    Progressing to become the patient-centric global biopharma leader April 2011 Alison, living with rheumatoid arthritis

  2. Slide 2: Disclaimer and safe harbour

    Slide 2: Disclaimer and safe harbour

    Disclaimer and safe harbour Forward-looking statements: This presentation includes “forward-looking statements” relating to UCB group of companies (“UCB”) that are subject to known and unknown risks and uncertainties, many of which are outside of UCB’s control and are difficult to predict, that may

  3. Slide 3: UCB: to be patient-centric global biopharma leader

    Slide 3: UCB: to be patient-centric global biopharma leader

    UCB: to be patient-centric global biopharma leader 3 Focus: Immunology and Central Nervous System R&D spend: 22% of revenue About 203 000 patients treated with UCB’s new core products Operations in more than 40 countries About 8 500 employees globally Stephanie, living with rheumatoid arthritis 3

  4. Slide 4: 2010 financial highlights

    Slide 4: 2010 financial highlights

    2010 financial highlights Revenue of € 3 218 million 3% • Strong Cimzia®, Vimpat® and Neupro® • Strong Keppra® sales in EU and venlafaxine XR in U.S. Underlying profitability (Recurring EBITDA) 5% of € 731 million Core EPS of € 1.991, above guidance 15% 1. based on 180 million shares outstanding 4

  5. Slide 5: 203 000 patients have now been treated

    Slide 5: 203 000 patients have now been treated

    203 000 patients have now been treated An increase of 88% versus December 2009 UCB is becoming the Patient-Centric global biopharmaceutical leader Fast response for predictable outcomes 22 000 patients prescribed Expected peak sales of at least € 1.5 billion1 When monotherapy is no longer enough 108

  6. Slide 6: Core Medicines

    Slide 6: Core Medicines

    Core Medicines Brett, living with crohn’s disease

  7. Slide 7: Cimzia

    Slide 7: Cimzia

    Cimzia® Fast response for predictable outcomes Net sales increased by 163% 2010 2009 € million net sales net sales North America 166 70 Europe 31 5 ROW 1 0 Total 198 75 ~ 22 000 patients on Cimzia® Rheumatoid arthritis - Fast response for predictable outcomes • Fast response with Cimzia® means • Imp

  8. Slide 8: Cimzia provides a fast response for results that last

    Slide 8: Cimzia provides a fast response for results that last

    Cimzia® provides a fast response for results that last1 The degree and speed of response with Cimzia® was highly predictive of outcomes at 52 weeks3 Available data suggest that a clinical response Predicting response at week 12 can improve is usually achieved within the first 12 weeks of therapeutic

  9. Slide 9: Cimzia in rheumatoid arthritis – U.S.

    Slide 9: Cimzia in rheumatoid arthritis – U.S.

    Cimzia® in rheumatoid arthritis – U.S. Gaining use even in an entrenched marketplace Cimzia® RA indexed vs Total Market: 240 220 RA Indexed Monthly Rx 200 180 160 140 120 100 80 10 10 10 10 10 0 0 0 0 0 0 0 ‐1 r ‐1 t ‐1 ‐1 ‐1 ‐1 ‐1 b‐ p‐ g‐ c‐ n‐ n l v ar ay Ju Ap Oc Au De Fe Se Ju No Ja M M Cimzia®

  10. Slide 10: Cimzia for Crohn's disease - U.S.

    Slide 10: Cimzia for Crohn's disease - U.S.

    Cimzia® for Crohn's disease - U.S. An important new option for U.S. patients Cimzia® CD indexed vs Total Market: 160 150 CD Indexed Monthly Rx 140 130 120 110 100 90 80 10 10 0 10 10 0 0 10 0 0 0 0 ‐1 r ‐1 t ‐1 1 ‐1 ‐1 ‐1 b‐ p‐ g‐ c‐ n‐ v‐ n l ar ay Ju Ap Oc Au De Fe Se Ju No Ja M M Cimzia® Nrx Tota

  11. Slide 11: Cimzia: Roll-out in Europe and Rest of the World

    Slide 11: Cimzia: Roll-out in Europe and Rest of the World

    Cimzia® Roll-out in Europe and Rest of the World Quarterly sales evolution since launch € million 15 12 1st launch in RA 9 6 3 0 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2008 2009 2010 11

  12. Slide 12: Cimzia roll-out

    Slide 12: Cimzia roll-out

    Cimzia® roll-out Launched in 20 countries, continued launch roll-out 2009 2010 Launch Countries Q2 2009 Q3 2009 Q4 2009 Q1 2010 Q2 2010 Q3 2010 Q4 2010 Ireland Italy Switzerland France Greece Australia Slovakia 2010 Spain Launches Austria Belgium Hungary Finland Netherlands Sweden Norway UK Denmark

  13. Slide 13: Vimpat in epilepsy

    Slide 13: Vimpat in epilepsy

    Vimpat® in epilepsy When monotherapy is no longer enough… Net sales increased by 190% 2010 2009 € million net sales net sales North America 96 30 Europe 36 16 ROW 1 0 Total 133 46 ~ 108 000 patients on Vimpat® Epilepsy adjunctive therapy When monotherapy is no longer enough… • A new treatment option

  14. Slide 14: Vimpat – Improved seizure control

    Slide 14: Vimpat – Improved seizure control

    Vimpat® – Improved seizure control Regardless of patient’s concomitant therapy 14

  15. Slide 15: UCB's reputation amongst neurologists continues to grow

    Slide 15: UCB's reputation amongst neurologists continues to grow

    UCB’s status as the company with the best reputation amongst neurologists continues to grow Company with Best Reputation (Unaided) All Neurologists 50% UCB GlaxoSmithKline 45% Abbott Laboratories Pfizer 40% Ortho McNeil Novartis 35% Don't know None 30% 25% 20% 15% 10% 5% 0% July 2006, Feb 2007, Nov

  16. Slide 16: Vimpat - U.S.

    Slide 16: Vimpat - U.S.

    Vimpat® - U.S. Successful launch in the AED market 200 180 Indexed Monthly Rx 160 140 120 100 80 10 10 10 10 10 10 0 10 0 0 0 0 r ‐1 t ‐1 l‐1 ‐1 ‐1 n‐ b‐ p‐ g‐ c‐ n‐ v‐ ar ay Ju Ap Oc Au De Fe Se Ju No Ja M M Vimpat® Trx Total Market Trx Vimpat® Nrx Total Market Nrx * Total Market: Carbamazepine, Ga

  17. Slide 17: Vimpat is the add-on of choice for epilepsy patients

    Slide 17: Vimpat is the add-on of choice for epilepsy patients

    Physicians report Vimpat® is the add-on of choice for epilepsy patients and is being used earlier in the treatment algorithm ® Physicians Physicians report: Vimpat® is report: Vimpat is the the agent agent of choice when selecting an of choice when selecting an 30% add-on therapy for epilepsy add-on

  18. Slide 18: Vimpat in epilepsy: roll-out in Europe and Rest of World

    Slide 18: Vimpat in epilepsy: roll-out in Europe and Rest of World

    Vimpat® in epilepsy Roll-out in Europe and Rest of World Quarterly sales evolution since launch € million 12 9 6 3 0 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2008 2009 2010 18

  19. Slide 19: Vimpat roll-out

    Slide 19: Vimpat roll-out

    Vimpat® roll-out Launched in 22 countries, continued launch roll-out 2008 2009 2010 Launch Q3 2008 Q4 2008 Q1 2009 Q2 2009 Q3 2009 Q4 2009 Q1 2010 Q2 2010 Q3 2010 Q4 2010 Countries Canada Mexico Italy 2010 Russia Launches Australia Czech Belgium Finland Switzerland France Spain Norway U.S. 2009 Neth

  20. Slide 20: Neupro roll-out in Europe and Rest of the World

    Slide 20: Neupro roll-out in Europe and Rest of the World

    Neupro® roll-out in Europe and Rest of the World 24h continuous delivery by transdermal patch Net sales increased by 34% 2010 2009 € million net sales net sales Europe 81 60 ROW 1 0 ~ 73 000 patients on Neupro® Parkinson’s disease and restless legs syndrome 24h continuous delivery by transdermal pat

  21. Slide 21: Neupro - rotigotine transdermal patch

    Slide 21: Neupro - rotigotine transdermal patch

    Neupro® - rotigotine transdermal patch Continued launch roll-out Quarterly sales evolution € million 25 New patient launch 20 PD & RLS 15 10 5 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2008 2009 2010 21

  22. Slide 22: Neupro - rotigotine transdermal patch

    Slide 22: Neupro - rotigotine transdermal patch

    Neupro® - rotigotine transdermal patch Continued launch roll-out 2006 2007 2008 2009 2010 Launch Countries Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Mexico 2010 Poland Launches Romania Czech Republic 2009 Netherlands Launches Australia Hong-Kong Finland 2008 Italy Launches Slovakia

  23. Slide 23: Keppra franchise

    Slide 23: Keppra franchise

    Keppra® franchise Market leadership in Europe and Rest of the World 2010 2009 € million Actual CER net sales net sales Europe 606 545 11% 10% North America 278 320 -13% -18% Rest of World 58 48 21% 6% Total 942 913 3% 0% Loss of exclusivity in the U.S. (November 2008) Loss of exclusivity in the E.U.

  24. Slide 24: 2010 Financial Performance

    Slide 24: 2010 Financial Performance

    2010 Financial Performance Christer, living with Parkinson’s disease

  25. Slide 25: 2010 Financial highlights

    Slide 25: 2010 Financial highlights

    2010 Financial highlights Revenue of € 3 218 million • Generic competition to mature products compensated by Cimzia®, Vimpat® and 3% Neupro®; strong Keppra® sales in EU and venlafaxine XR in U.S. Total operating expenses € 1 698 million • Increased launch expenses for Cimzia®, Vimpat® and Neupro® 4%

  26. Slide 26: Net sales of major and new products

    Slide 26: Net sales of major and new products

    Net sales of major and new products Net sales 2010: € 2 786 million In € million Core products Cimzia® +163% 198 Core products combined sales of € 413 million Vimpat® 133 up by 127% in the first full year of sales – on +190% track to meet peak sales guidance Neupro® +34% 82 Keppra® 1 +3% 942 Zyrtec®

  27. Slide 27: 2010 net sales

    Slide 27: 2010 net sales

    2010 net sales Solid growth from core products € million Core Mature products products - 128 + 231 Cimzia® Vimpat® 2009 2010 net2010 Neupro® net sales sales Net Sales € 2 683 € 2 786 million 2009 million Net 1 431 Sales 4% 1 379 27

  28. Slide 28: Recurring EBITDA

    Slide 28: Recurring EBITDA

    Recurring EBITDA Consistent solid underlying profitability Actual Variance € million 2010 2009 Actual CER Revenue 3 218 3 116 3% 0% Net sales 2 786 2 683 4% 0% Royalty income & fees 220 227 -3% -7% Other revenue 212 206 3% 0% Gross profit 2 165 2 091 4% - 1% Marketing & selling expenses -797 -781 2%

  29. Slide 29: Net profit

    Slide 29: Net profit

    Net profit Strong REBIT impacted by non-cash, one-time charges Actual Variance € million 2010 2009 Actual CER Recurring EBIT 467 453 3% -7% Impairment charges -223 -126 78% 73% Restructuring expenses -40 -73 -46% -48% Gain on disposals 49 594 n.s. n.s. Other non recurring expenses -49 -11 n.s. n.s.

  30. Slide 30: 2010 cash flows

    Slide 30: 2010 cash flows

    2010 cash flows Investing Operating Financing1 activities activities activities € -63 m € 506 m € -440 m FY 2009 FY 2010 cash cash 87% € 466 € 477 million million 1 1 Includes effect of exchange rate fluctuations 30

  31. Slide 31: Net debt evolution

    Slide 31: Net debt evolution

    Net debt evolution Strong free cash flow reduces net debt by 15% € million 31 Dec 2010 31 Dec 2009 Net debt -1 525 -1 752 Liquid assets 498 491 Financial debt -2 023 -2 243 Net Debt (€ million) Net Debt/REBITDA 2 443 2 500 3.5 3.3x 3.0 2 000 1 915 2.6x 1 752 2.5x 2.5 1 525 1 500 2.1x 2.0 1.5 1 000 1

  32. Slide 32: 2011 financial outlook

    Slide 32: 2011 financial outlook

    2011 financial outlook Revenue is expected between € 3.0 and € 3.1 billion Recurring EBITDA expected to be in the range between € 650 and 680 million Core EPS expected to reach approximately € 1.60 to 1.701 1. based on 180 million shares outstanding, see appendix for Core EPS calculation methodology

  33. Slide 33: Advancing the pipeline

    Slide 33: Advancing the pipeline

    Advancing the pipeline Esperanza, living with RLS

  34. Slide 34: Development pipeline with significant progress: CNS

    Slide 34: Development pipeline with significant progress: CNS

    Development pipeline with significant progress Central Nervous System (CNS) Phase 1 Phase 2 Phase 3 Regulatory status Neupro® (rotigotine) Filed CRL* Adv. Parkinson's disease (U.S.) November Dec 20082008 Neupro® (rotigotine) CRL* Restless legs syndrome (U.S.) Dec 2008 Vimpat® (lacosamide) Results Ep

  35. Slide 35: Vimpat in epilepsy: increasing patient access

    Slide 35: Vimpat in epilepsy: increasing patient access

    Vimpat® in epilepsy Increasing patient access Monotherapy in the treatment of partial-onset seizures • Phase 3 trial in EU initiated Phase 1 Phase 2 Phase 3 Vimpat® Results Monotherapy (U.S.) Q2 2013 Vimpat® Results Q4 2014 Monotherapy (EU) Veronica, living with epilepsy Paediatric1 development in p

  36. Slide 36: Vimpat in epilepsy – monotherapy (EU)

    Slide 36: Vimpat in epilepsy – monotherapy (EU)

    Vimpat® in epilepsy – monotherapy (EU) Phase 3 programme started – results Q4 2014 Phase 3 trial initiated • adults ≥16 years experiencing POS or PGTCS • ~1000 subjects across 120 sites in EU, Canada, Australia, and other regions • multicenter, double-blind, double-dummy, randomized, positive-contro

  37. Slide 37: Brivaracetam in epilepsy

    Slide 37: Brivaracetam in epilepsy

    Brivaracetam in epilepsy New Phase 3 trial started – first results H1 2013 Phase 3 trial currently recruiting • Refractory patient population (≥16 to 80 years ) with partial onset seizures (POS) • 720 patients across 120 sites worldwide • Multicenter, placebo-controlled, randomized efficacy trial Pl

  38. Slide 38: Neupro in the U.S.

    Slide 38: Neupro in the U.S.

    Neupro® in the U.S. Parkinson’s disease & restless legs syndrome FDA Complete Response Letter (December 2008) • “Substantial evidence of effectiveness in advanced Parkinson’s disease and restless legs syndrome” Development of room temperature-stable patch formulation on track Complete Response Lette

  39. Slide 39: Development pipeline with significant progress: Immunology

    Slide 39: Development pipeline with significant progress: Immunology

    Development pipeline with significant progress Immunology Phase 1 Phase 2 Phase 3 Regulatory status Cimzia® (certolizumab pegol) Positive Rheumatoid arthritis (Japan) results Cimzia® (certolizumab pegol) Results Ankylosing spondylitis Q4 2011 Cimzia® (certolizumab pegol) Results Psoriatic arthritis

  40. Slide 40: Cimzia in further arthritis indications

    Slide 40: Cimzia in further arthritis indications

    Cimzia® in further arthritis indications Increasing patient access Psoriatic arthritis (PsA) - Phase 3 trials ongoing • Two active arms: monthly (400 mg) and two week (200 mg) dosing • Time-frame: 24 + 48 weeks Phase 1 Phase 2 Phase 3 Cimzia® Results Psoriatic arthritis Q4 2011 Deonna, living with r

  41. Slide 41: Cimzia in further arthritis indications

    Slide 41: Cimzia in further arthritis indications

    Cimzia® in further arthritis indications Increasing patient access Juvenile rheumatoid arthritis (JRA) • Discussion ongoing with EU and U.S. regulators to finalise the study Phase 3 design Phase 1 Phase 2 Phase 3 Cimzia® Juvenile RA Alison, living with rheumatoid arthritis Rheumatoid arthritis (Japa

  42. Slide 42: Epratuzumab in SLE

    Slide 42: Epratuzumab in SLE

    Epratuzumab in SLE Phase 3 programme started – results H1 2014 Phase 3 trials currently recruiting • Two confirmatory Phase 3 studies (Embody 1 & Embody 2) • Moderate to severe patient population • 780 patients/trial across 130 sites worldwide • Multicenter, placebo-controlled, randomized efficacy s

  43. Slide 43: CDP7851 in bone loss disorders

    Slide 43: CDP7851 in bone loss disorders

    CDP7851 in bone loss disorders Novel therapy with strong potential Development of novel anabolic therapy • Antibody to sclerostin potentially treating bone loss disorders, incl. osteoporosis Collaborative project with Amgen Phase 2 trials ongoing • Phase 2 study in post-menopausal osteoporosis • Est

  44. Slide 44: Olokizumab in rheumatoid arthritis

    Slide 44: Olokizumab in rheumatoid arthritis

    Olokizumab (CDP6038, anti-IL-6) in rheumatoid arthritis Phase 2b programme started – results Q3 2012 Phase 2b trial currently recruiting • Active RA having previously failed TNF blocker therapy • 220 patients across approximately 100 sites in U.S. and Europe • Randomised, double-blind placebo-contro

  45. Slide 45: Additional external pipeline options

    Slide 45: Additional external pipeline options

    Additional external pipeline options Therapeutic area / Stage of development Development path Indication + Partner SYN115 CNS – Phase 2 trial ongoing; (A2a) Parkinson’s Phase 2b to start in disease Q1 2011 Synosia/Biotie to complete Phase 2; SYN118 CNS – Phase 2 trial ongoing UCB to take over (HPPD)

  46. Slide 46: UCB NewMedicines

    Slide 46: UCB NewMedicines

    UCB NewMedicines 46 Juan, living with restless legs syndrome 46

  47. Slide 47: UCB NewMedicines strategy and business model

    Slide 47: UCB NewMedicines strategy and business model

    UCB NewMedicines strategy and business model A new R&D paradigm to deliver Partnering and virtualisation to differentiated drugs complement internal capabilities Deliver differentiated molecules Increase success rates Innovative targets (Academic/biotech) Enhance scientific excellence SEGMENTED Whol

  48. Slide 48: Our model addresses the industry's low R&D success rates

    Slide 48: Our model addresses the industry's low R&D success rates

    Our model addresses the industry’s low R&D developmental and commercial success rates 89% of molecules in development fail** 42% of Phase 3 trials fail* 70% launched products fail to recoup initial investment Pre-clinical Clinical (all phases) Commercial Reasons for attrition 1/10 2/1000 3/10 **Isma

  49. Slide 49: Attrition rates of failed Phase candidates reveal POC paradigm benefits

    Slide 49: Attrition rates of failed Phase candidates reveal POC paradigm benefits

    Attrition rates of failed Phase 3 candidates reveals POC Paradigm benefits OF 42% of Phase 3 trials fail* H ROBUSTNESS ROBUSTNESS ENDPOINT High Biomarker DESIRED QUADRANT FOR MOST OF PORTFOLIO OF BIOMARKER Low POC Attrition rate 63% Attrition rate 25% REGISTERABLE OBJECTIVITY OBJECTIVITY AND AND LEA

  50. Slide 50: Paradigm to pick winners and kill early

    Slide 50: Paradigm to pick winners and kill early

    Paradigm to pick winners and kill early TEST THE THEORY - LEARN CONFIRM THE THEORY APPROVAL POC at Ph 2B – AND robust POC-light IN MAN register-able LAUNCH FIH – – endpoints endpoint including target for internal CANDIDATE engagement decision making APPROVAL biomarker 50

  51. Slide 51: UCB2892 (H3 antagonist)

    Slide 51: UCB2892 (H3 antagonist)

    UCB2892 (H3 antagonist) January 2011: Robust data-driven decision making Termination of Phase 1 programme for UCB2892, an H3 antagonist with potential for cognitive disorders • Results demonstrated uncompetitive clinical profile UCB’s new paradigm for robust decision-making: demonstrable speed and c

  52. Slide 52: UCB is delivering on... to achieve sustainable company growth

    Slide 52: UCB is delivering on... to achieve sustainable company growth

    UCB is delivering on… Financial targets Core product launches – Cimzia®, Vimpat®, Neupro® Increased patient reach Strong pipeline … to achieve sustainable company growth 52

  53. Slide 53: UCB's sustainable future growth

    Slide 53: UCB's sustainable future growth

    UCB's sustainable future growth Cimzia®, Vimpat® and Neupro® trigger company growth Intense growth Breakthrough Company Launch a new generation of therapies offering growth breakthrough innovation to Cimzia®, Vimpat®, patients with severe disease Neupro® Realise the full commercial • Optimise mature

  54. Slide 54: Appendix

    Slide 54: Appendix

    Appendix 54 54

  55. Slide 55: Major milestones expected in 2011

    Slide 55: Major milestones expected in 2011

    Major milestones expected in 2011 Cimzia® in rheumatoid arthritis (Japan) • Phase 3 headline results H1 2011 9 Xyrem® for fibromyalgia • Feedback from the European authorities H1 2011 9 CDP7851 (anti-sclerostin) in post-menopausal osteoporosis • Phase 2 headline results Q2 2011 Vimpat® in epilepsy –

  56. Slide 56: Geographic and therapeutic breakdown

    Slide 56: Geographic and therapeutic breakdown

    Geographic and therapeutic breakdown Net sales 2010: € 2 786 million Focused From primary care to specialist physicians CNS and immunology Core markets: U.S., EU, Japan, selected emerging markets Specialist physicians contacted by small and efficient sales forces France 6% Germany 13% North Other CN

  57. Slide 57: Core EPS

    Slide 57: Core EPS

    Core EPS Actual € million Variance 2010 2009 Actual Net profit 103 513 -80% After-tax non-recurring items & 216 -297 n.s. financial one-offs Profit from discontinued operation +1 -7 n.s. Tax one-offs -81 +17 n.s. Adusted net profit1 239 226 6% + Amortisation of intangibles +173 +128 36% - Taxes on a

  58. Slide 58: 2010 balance sheet

    Slide 58: 2010 balance sheet

    2010 balance sheet € million Cash and Cash Equivalents 494 Other Current Other Current 1 545 Liabilities Assets 1 237 Other Non- 308 Current Debt Current Assets 879 809 Other Non- Current Liabilities Intangible Assets 1 641 1 715 Non-Current Debt Goodwill Shareholder’s 4 718 4 4695 592 Equity: 47% T

  59. Slide 59: Debt maturity profile

    Slide 59: Debt maturity profile

    Debt maturity profile Better aligned to expected CF generation € million 1 000 500 500 750 500 299 0 2011 2012 2013 2014 2015 2016 Revolving Credit Facility Belgian retail bond Convertible Institutional eurobond € 750 million 5.75% Belgian retail bonds due November 2014 € 1 000 million Revolving cre

  60. Slide 60: Shareholder structure

    Slide 60: Shareholder structure

    Shareholder structure1 Strong and stable shareholder base Tubize 36% “Free float” investors by region Concert 14% North America 40% Other investors, 15% Other institutional Cont.Europe investors 14% 20% Capital Research Unidentified UK & 12% 15% Ireland 8% Wellington Belgium 3% 23% 1. Source: Global

  61. Slide 61: Update on clinical development

    Slide 61: Update on clinical development

    Update on clinical development • Phase 3 in psoriatic arthritis ongoing • Phase 3 in ankylosing spondylitis ongoing • Phase 3 design in juvenile rheumatoid arthritis under discussion • Phase 3 in rheumatoid arthritis in Japan completed positively • Phase 3 in monotherapy (U.S.) ongoing • Phase 3 in

  62. Slide 62: Epilepsy: strong need for new treatment options

    Slide 62: Epilepsy: strong need for new treatment options

    Epilepsy Strong need for new treatment options High unmet medical need in ~1/3 Epilepsy types and treatments of treated epilepsy patients algorithm Monotherapy Add-on therapy 25-30% Partial Onset Seizures 29% 27% 50% 20-25% Primary Generalised 19% Seizures 25% Controlled on 1st monotherapy Uncontrol

  63. Slide 63: Your UCB Investor Relations team

    Slide 63: Your UCB Investor Relations team

    Your UCB Investor Relations team Antje Witte, Vice President Investor Relations • Phone: +32 2 559 9414 • E-mail: antje.witte@ucb.com Michael Tuck-Sherman, Investor Relations Manager • Phone: +32 2 559 9712 • E-mail: michael.tuck-sherman@ucb.com Isabelle Ghellynck, Investor Relations Project Manager

Source: Internet Archive copy of ucb.com

More decks from Ucb S.A.

All 41 Ucb decks